Elevated serum levels of glial fibrillary acidic protein are associated with covert hepatic encephalopathy in patients with cirrhosis
Background & Aims: Blood biomarkers facilitating the diagnosis of covert hepatic encephalopathy (CHE) in patients with cirrhosis are lacking. Astrocyte swelling is a major component of hepatic encephalopathy. Thus, we hypothesised that glial fibrillary acidic protein (GFAP), the major interm...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-04-01
|
| Series: | JHEP Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589555923000022 |
| _version_ | 1827980699171291136 |
|---|---|
| author | Simon Johannes Gairing Sven Danneberg Leonard Kaps Michael Nagel Eva Maria Schleicher Charlotte Quack Sinah Engel Stefan Bittner Peter Robert Galle Jörn Markus Schattenberg Marcus-Alexander Wörns Felix Luessi Jens Uwe Marquardt Christian Labenz |
| author_facet | Simon Johannes Gairing Sven Danneberg Leonard Kaps Michael Nagel Eva Maria Schleicher Charlotte Quack Sinah Engel Stefan Bittner Peter Robert Galle Jörn Markus Schattenberg Marcus-Alexander Wörns Felix Luessi Jens Uwe Marquardt Christian Labenz |
| author_sort | Simon Johannes Gairing |
| collection | DOAJ |
| description | Background & Aims: Blood biomarkers facilitating the diagnosis of covert hepatic encephalopathy (CHE) in patients with cirrhosis are lacking. Astrocyte swelling is a major component of hepatic encephalopathy. Thus, we hypothesised that glial fibrillary acidic protein (GFAP), the major intermediate filament of astrocytes, might facilitate early diagnosis and management. This study aimed to investigate the utility of serum GFAP (sGFAP) levels as a biomarker of CHE. Methods: In this bicentric study, 135 patients with cirrhosis, 21 patients with ongoing harmful alcohol use and cirrhosis, and 15 healthy controls were recruited. CHE was diagnosed using psychometric hepatic encephalopathy score. sGFAP levels were measured using a highly sensitive single-molecule array (SiMoA) immunoassay. Results: In total, 50 (37%) people presented with CHE at study inclusion. Participants with CHE displayed significantly higher sGFAP levels than those without CHE (median sGFAP, 163 pg/ml [IQR 136; 268] vs. 106 pg/ml [IQR 75; 153]; p <0.001) or healthy controls (p <0.001). sGFAP correlated with results in psychometric hepatic encephalopathy score (Spearman's ρ = −0.326, p <0.001), model for end-stage liver disease score (Spearman's ρ = 0.253, p = 0.003), ammonia (Spearman’s ρ = 0.453, p = 0.002), and IL-6 serum levels (Spearman's ρ = 0.323, p = 0.006). Additionally, sGFAP levels were independently associated with the presence of CHE in multivariable logistic regression analysis (odds ratio 1.009; 95% CI 1.004–1.015; p <0.001). sGFAP levels did not differ between patients with alcohol-related cirrhosis vs. patients with non-alcohol-related cirrhosis or between patients with ongoing alcohol use vs. patients with discontinued alcohol use.Conclusions: sGFAP levels are associated with CHE in patients with cirrhosis. These results suggest that astrocyte injury may already occur in patients with cirrhosis and subclinical cognitive deficits and that sGFAP could be explored as a novel biomarker. Impact and implications: Blood biomarkers facilitating the diagnosis of covert hepatic encephalopathy (CHE) in patients with cirrhosis are lacking. In this study, we were able to demonstrate that sGFAP levels are associated with CHE in patients with cirrhosis. These results suggest that astrocyte injury may already occur in patients with cirrhosis and subclinical cognitive deficits and that sGFAP could be explored as a novel biomarker. |
| first_indexed | 2024-04-09T21:56:27Z |
| format | Article |
| id | doaj.art-701ec0faf173408db3245c6365e267e6 |
| institution | Directory Open Access Journal |
| issn | 2589-5559 |
| language | English |
| last_indexed | 2024-04-09T21:56:27Z |
| publishDate | 2023-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JHEP Reports |
| spelling | doaj.art-701ec0faf173408db3245c6365e267e62023-03-24T04:23:15ZengElsevierJHEP Reports2589-55592023-04-0154100671Elevated serum levels of glial fibrillary acidic protein are associated with covert hepatic encephalopathy in patients with cirrhosisSimon Johannes Gairing0Sven Danneberg1Leonard Kaps2Michael Nagel3Eva Maria Schleicher4Charlotte Quack5Sinah Engel6Stefan Bittner7Peter Robert Galle8Jörn Markus Schattenberg9Marcus-Alexander Wörns10Felix Luessi11Jens Uwe Marquardt12Christian Labenz13Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany; Cirrhosis Center Mainz (CCM), University Medical Center of the Johannes Gutenberg-University, Mainz, GermanyDepartment of Medicine I, University Hospital Schleswig-Holstein, Lübeck, GermanyDepartment of Internal Medicine I, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany; Cirrhosis Center Mainz (CCM), University Medical Center of the Johannes Gutenberg-University, Mainz, GermanyDepartment of Internal Medicine I, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany; Cirrhosis Center Mainz (CCM), University Medical Center of the Johannes Gutenberg-University, Mainz, Germany; Department of Gastroenterology, Hematology, Oncology and Endocrinology, Klinikum Dortmund, GermanyDepartment of Internal Medicine I, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany; Cirrhosis Center Mainz (CCM), University Medical Center of the Johannes Gutenberg-University, Mainz, GermanyDepartment of Internal Medicine I, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany; Cirrhosis Center Mainz (CCM), University Medical Center of the Johannes Gutenberg-University, Mainz, GermanyDepartment of Neurology, University Medical Center of the Johannes Gutenberg-University, Mainz, GermanyDepartment of Neurology, University Medical Center of the Johannes Gutenberg-University, Mainz, GermanyDepartment of Internal Medicine I, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany; Cirrhosis Center Mainz (CCM), University Medical Center of the Johannes Gutenberg-University, Mainz, GermanyDepartment of Internal Medicine I, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany; Metabolic Liver Research Program, University Medical Center of the Johannes Gutenberg-University, Mainz, GermanyDepartment of Internal Medicine I, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany; Cirrhosis Center Mainz (CCM), University Medical Center of the Johannes Gutenberg-University, Mainz, Germany; Department of Gastroenterology, Hematology, Oncology and Endocrinology, Klinikum Dortmund, GermanyDepartment of Neurology, University Medical Center of the Johannes Gutenberg-University, Mainz, GermanyDepartment of Medicine I, University Hospital Schleswig-Holstein, Lübeck, GermanyDepartment of Internal Medicine I, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany; Cirrhosis Center Mainz (CCM), University Medical Center of the Johannes Gutenberg-University, Mainz, Germany; Corresponding author. Address: Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg-University, Langenbeckstrasse 1, 55131 Mainz, Germany. Tel.: +49-6131-17-2380; Fax: +49-6131-17-477282..Background & Aims: Blood biomarkers facilitating the diagnosis of covert hepatic encephalopathy (CHE) in patients with cirrhosis are lacking. Astrocyte swelling is a major component of hepatic encephalopathy. Thus, we hypothesised that glial fibrillary acidic protein (GFAP), the major intermediate filament of astrocytes, might facilitate early diagnosis and management. This study aimed to investigate the utility of serum GFAP (sGFAP) levels as a biomarker of CHE. Methods: In this bicentric study, 135 patients with cirrhosis, 21 patients with ongoing harmful alcohol use and cirrhosis, and 15 healthy controls were recruited. CHE was diagnosed using psychometric hepatic encephalopathy score. sGFAP levels were measured using a highly sensitive single-molecule array (SiMoA) immunoassay. Results: In total, 50 (37%) people presented with CHE at study inclusion. Participants with CHE displayed significantly higher sGFAP levels than those without CHE (median sGFAP, 163 pg/ml [IQR 136; 268] vs. 106 pg/ml [IQR 75; 153]; p <0.001) or healthy controls (p <0.001). sGFAP correlated with results in psychometric hepatic encephalopathy score (Spearman's ρ = −0.326, p <0.001), model for end-stage liver disease score (Spearman's ρ = 0.253, p = 0.003), ammonia (Spearman’s ρ = 0.453, p = 0.002), and IL-6 serum levels (Spearman's ρ = 0.323, p = 0.006). Additionally, sGFAP levels were independently associated with the presence of CHE in multivariable logistic regression analysis (odds ratio 1.009; 95% CI 1.004–1.015; p <0.001). sGFAP levels did not differ between patients with alcohol-related cirrhosis vs. patients with non-alcohol-related cirrhosis or between patients with ongoing alcohol use vs. patients with discontinued alcohol use.Conclusions: sGFAP levels are associated with CHE in patients with cirrhosis. These results suggest that astrocyte injury may already occur in patients with cirrhosis and subclinical cognitive deficits and that sGFAP could be explored as a novel biomarker. Impact and implications: Blood biomarkers facilitating the diagnosis of covert hepatic encephalopathy (CHE) in patients with cirrhosis are lacking. In this study, we were able to demonstrate that sGFAP levels are associated with CHE in patients with cirrhosis. These results suggest that astrocyte injury may already occur in patients with cirrhosis and subclinical cognitive deficits and that sGFAP could be explored as a novel biomarker.http://www.sciencedirect.com/science/article/pii/S2589555923000022CHEHEGFAPBiomarkersComplications of cirrhosisPsychometric hepatic encephalopathy score |
| spellingShingle | Simon Johannes Gairing Sven Danneberg Leonard Kaps Michael Nagel Eva Maria Schleicher Charlotte Quack Sinah Engel Stefan Bittner Peter Robert Galle Jörn Markus Schattenberg Marcus-Alexander Wörns Felix Luessi Jens Uwe Marquardt Christian Labenz Elevated serum levels of glial fibrillary acidic protein are associated with covert hepatic encephalopathy in patients with cirrhosis JHEP Reports CHE HE GFAP Biomarkers Complications of cirrhosis Psychometric hepatic encephalopathy score |
| title | Elevated serum levels of glial fibrillary acidic protein are associated with covert hepatic encephalopathy in patients with cirrhosis |
| title_full | Elevated serum levels of glial fibrillary acidic protein are associated with covert hepatic encephalopathy in patients with cirrhosis |
| title_fullStr | Elevated serum levels of glial fibrillary acidic protein are associated with covert hepatic encephalopathy in patients with cirrhosis |
| title_full_unstemmed | Elevated serum levels of glial fibrillary acidic protein are associated with covert hepatic encephalopathy in patients with cirrhosis |
| title_short | Elevated serum levels of glial fibrillary acidic protein are associated with covert hepatic encephalopathy in patients with cirrhosis |
| title_sort | elevated serum levels of glial fibrillary acidic protein are associated with covert hepatic encephalopathy in patients with cirrhosis |
| topic | CHE HE GFAP Biomarkers Complications of cirrhosis Psychometric hepatic encephalopathy score |
| url | http://www.sciencedirect.com/science/article/pii/S2589555923000022 |
| work_keys_str_mv | AT simonjohannesgairing elevatedserumlevelsofglialfibrillaryacidicproteinareassociatedwithcoverthepaticencephalopathyinpatientswithcirrhosis AT svendanneberg elevatedserumlevelsofglialfibrillaryacidicproteinareassociatedwithcoverthepaticencephalopathyinpatientswithcirrhosis AT leonardkaps elevatedserumlevelsofglialfibrillaryacidicproteinareassociatedwithcoverthepaticencephalopathyinpatientswithcirrhosis AT michaelnagel elevatedserumlevelsofglialfibrillaryacidicproteinareassociatedwithcoverthepaticencephalopathyinpatientswithcirrhosis AT evamariaschleicher elevatedserumlevelsofglialfibrillaryacidicproteinareassociatedwithcoverthepaticencephalopathyinpatientswithcirrhosis AT charlottequack elevatedserumlevelsofglialfibrillaryacidicproteinareassociatedwithcoverthepaticencephalopathyinpatientswithcirrhosis AT sinahengel elevatedserumlevelsofglialfibrillaryacidicproteinareassociatedwithcoverthepaticencephalopathyinpatientswithcirrhosis AT stefanbittner elevatedserumlevelsofglialfibrillaryacidicproteinareassociatedwithcoverthepaticencephalopathyinpatientswithcirrhosis AT peterrobertgalle elevatedserumlevelsofglialfibrillaryacidicproteinareassociatedwithcoverthepaticencephalopathyinpatientswithcirrhosis AT jornmarkusschattenberg elevatedserumlevelsofglialfibrillaryacidicproteinareassociatedwithcoverthepaticencephalopathyinpatientswithcirrhosis AT marcusalexanderworns elevatedserumlevelsofglialfibrillaryacidicproteinareassociatedwithcoverthepaticencephalopathyinpatientswithcirrhosis AT felixluessi elevatedserumlevelsofglialfibrillaryacidicproteinareassociatedwithcoverthepaticencephalopathyinpatientswithcirrhosis AT jensuwemarquardt elevatedserumlevelsofglialfibrillaryacidicproteinareassociatedwithcoverthepaticencephalopathyinpatientswithcirrhosis AT christianlabenz elevatedserumlevelsofglialfibrillaryacidicproteinareassociatedwithcoverthepaticencephalopathyinpatientswithcirrhosis |